Abstract:HZ-H08905 is a first-class and potent CK1ε/PI3Kδ dual inhibitor with nano-molar inhibitory potency at the enzyme and cellular level. In vivo tumor growth inhibition is also observed in multiple B-cell lymphoma xenograft mouse model including OCI-LY10 and SU-DHL-6. HZ-H08905 has unique structure and activity profile distinct from other PI3Kδ inhibitors in development: 1) dual inhibition of CK1ε and PI3Kδ may exert synergistic effects through inhibiting both CK1ε/Wnt signaling and PI3K signaling in malignant lymphocytes, 2) dual inhibition of CK1ε and PI3Kδ also enhance anti-tumor immunity through regulation of tumor microenvironment; 3) preclinical studies also suggested an improved therapeutic window with a differentiated safety profile. HZ-H08905-101 is an ongoing Phase 1, first-in-human, open-label, multicenter, multiple-dose ascending and expansion study of oral HZ-H08905 monotherapy in patients with relapsed/ refractory advanced hematologic malignancies in China (CTR20213233). The aim of this study was to investigate the safety, tolerability, and pharmacokinetic properties of HZ-H08905, in order to determine the maximum tolerated dose (MTD) based on dose limiting toxicity (DLT) and assess preliminary anti-tumor activity in patients with non-Hodgkin lymphoma (NHL), including B-cell lymphoma and T-cell lymphoma. The phase Ia (dose escalation) part of the study was designed to determine MTD and recommended dose for expansion (RDE) of HZ-H08905. HZ-H08905 was administered orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The dose escalation part was initiated with a dose titration in the initial cohort, followed by a 3 + 3 design. Efficacy evaluable patients included all dosed patients who underwent their first response evaluation or discontinued therapy. Response was assessed at the beginning of cycle 3 and then every 12 weeks from cycle 3 and every 24 weeks from cycle 18, and was measured according to IWWM-7 for WM, or IWCLL 2018 for CLL/SLL, or Lugano 2014 criteria for other NHL. Safety was assessed in all patients. The preliminary results showed that HZ-H08905 was well tolerated and showed clinical activity in patients with R/R NHL, especially R/R PTCL. The efficacy, safety, and tolerability of HZ-H08905 in R/R PTCL patients at recommended phase II dose (RP2D) established in the phase I dose escalation and expansion part will be investigated in phase 2.

Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects

Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia

AC0010, a Novel BTK Inhibitor, Exerts Anti Leukemia Effects and Synergizes the Efficiency of Homoharringtonine in AML

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Dual CK1/PI3K Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

A Novel Multikinase Inhibitor R8 Exhibits Potent Inhibition on Cancer Cells Through Both Apoptosis and Autophagic Cell Death

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

2-Aminopyrimidine derivatives as selective dual inhibitors of JAK2 and FLT3 for the treatment of acute myeloid leukemia

Combination of RSK Inhibitor LJH-685 and FLT3 Inhibitor FF-10101 Promoted Apoptosis and Proliferation Inhibition of AML Cell Lines

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Design, Synthesis and Biological Evaluation of Novel Dithiocarbamate-Substituted Diphenylaminopyrimidine Derivatives As BTK Inhibitors

Identification of 2-Aminopyrimidine Derivatives As FLT3 Kinase Inhibitors with High Selectivity over C-Kit.

Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase

Design, synthesis, and evaluation of pyrido.[3,4–b]pyrazin-2(1 H )-one derivatives as potent FLT3 inhibitors

Design, Synthesis and Biological Evaluation of Novel 3-Substituted Pyrazolopyrimidine Derivatives As Potent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas

Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.